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BACKGROUND: Prenatal supplementation has been inversely associated with childhood, but not with infant, leukaemia.
METHODS: Mothers of 443 cases of infant leukaemia diagnosed during 1996–2006 and 324 frequency-matched controls completed
interviews. Associations were evaluated by unconditional logistic regression.
RESULTS: We observed no associations between prenatal vitamin (odds ratio (OR)¼0.79, 95% confidence interval (CI): 0.44–1.42) or
iron supplementation (OR¼1.07, 95% CI: 0.75–1.52) and infant leukaemia after adjustment for race/ethnicity and income. Similar
results were observed for leukaemia subtypes analysed separately.
CONCLUSION: The observed null associations may be attributable to high supplementation rates and/or national fortification
programmes.
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Leukaemias diagnosed in infants ( o12 months) are distinct
from leukaemias in older children/adolescents. Proportions of
acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia
(AML) cases are more similar among infants (47 vs 37%,
respectively; Linabery and Ross, 2008) and most cases (ALLs:
B75%, AMLs: B60%) have mixed lineage leukaemia (MLL) gene
rearrangements in their leukaemia cells (Pui et al, 1995; Greaves,
1996). Monozygotic twins with infant leukaemia have high
concordance (B100% vs children/adolescents: B10%; Greaves
et al, 2003). This observation, coupled with backtracking studies
demonstrating that MLL translocations are consistently present at
birth in infant cases (Gale et al, 1997), provides compelling
evidence of in utero initiation.
Although there are no established infant leukaemia risk factors,
prenatal vitamin supplementation has been inversely associated
with childhood ALL (see meta-analysis in Milne et al, 2010), with
one study implicating folic acid (Thompson et al, 2001). Sufficient
prenatal folic acid significantly reduces congenital abnormalities
(MRC Vitamin Study Research Group, 1991). Accordingly, the US
Public Health Service recommended X400mg of daily folate for
women of childbearing age in 1992 (Centers for Disease Control,
1992) and the United States and Canada implemented national
fortification programmes during 1996–1998 (Food and Drug
Administration, 1996; Ray et al, 2002b).
Prenatal iron supplementation (30mg per day) is also recom-
mended (Centers for Disease Control and Prevention, 1998) and
has been inconsistently associated with childhood leukaemia
(McKinney et al, 1999; Thompson et al, 2001; Wen et al, 2002;
Ross et al, 2005; Dockerty et al, 2007; Kwan et al, 2007; Milne et al,
2010). In this study, we investigate the effects of prenatal vitamin
and iron supplementation on infant leukaemia risk.
MATERIALS AND METHODS
Study methods have been previously published (Spector et al,
2005; Puumala et al, 2009, 2010; Johnson et al, 2010) and are
described briefly below.
Participant eligibility/identification
Cases. Infants (o12 months) with confirmed acute leukaemia
diagnoses during two periods (phase 1: January 1996 to October
2002, phase 2: January 2003 to December 2006) were eligible if they
were diagnosed/treated at the US or Canadian Children’s Oncology
Group (COG) institutions, did not have Down syndrome, had
physician approval for contact, had biological mothers who spoke
English or Spanish (phase 2), consented to participate, and were
available by telephone. Deceased cases were eligible.
Controls. Controls were frequency matched to cases on birth
year and location of residence. Controls had biological mothers
who spoke English or Spanish, consented to participate, and were
available by telephone.
In phase 1, controls were identified through random digit
dialing (RDD; Robison and Daigle, 1984). Owing to secular
telephone trends (Ross et al, 2004), RDD was undesirable for phase
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y2. Instead, rosters of potential controls, randomly selected on
anticipated birth year distribution, were requested from state birth
registries. Subjects were randomly selected from 15 state rosters. If
mothers refused, replacement subjects were selected until willing
participants were identified.
Data collection
In telephone interviews, mothers were asked whether they
consumed vitamin supplements anytime in the year before or
during the index pregnancy; in the year before pregnancy; early
in but before knowledge of pregnancy; and after knowledge
of pregnancy. For each time period, we asked what types of
supplements were consumed and whether or not supplements were
prescribed by healthcare professionals. Indicator variables were
created to assess vitamin use in the periconceptional period (year
before pregnancy and early in but before knowledge of pregnancy)
and from 1 year before through the index pregnancy. An
equivalent set of items concerned iron supplementation exceeding
the iron found in multivitamins.
Mothers of cases provided diagnostic information, including
results of Southern blot, RT–PCR, fluorescent in situ hybridisa-
tion, or other cytogenetics testing. Three independent reviewers
(SMD, NAH, JMH) evaluated the submitted materials to determine
whether there was evidence of MLL gene rearrangement (MLLþ,
n¼228), evidence of no rearrangement (MLL , n¼146), or
insufficient evidence (n¼69).
Statistical methods
Unconditional logistic regression (SAS 9.2, SAS Institute Inc., Cary,
NC, USA) was performed to quantify associations between
maternal supplement consumption and acute leukaemia among
combined cases, and among ALL, AML, MLLþ, and MLL  cases
analysed separately. Odds ratios (ORs) and 95% confidence
intervals (CIs) were produced. Potential confounders selected
a priori are listed in Table 1. Variables were retained in
multivariable models if they substantially (X10%) changed ln(OR)
estimates, including maternal race/ethnicity (white, black, Hispanic
or other) and household income in the child’s birth year
(p$30000, $30001–75000 or 4$75000). Adjustment for matching
factors (birth year and region of residence) did not materially alter
point estimates; hence, they were not included in the final models.
Institutional review boards at the University of Minnesota,
participating COG institutions, and states providing birth certifi-
cate data (as needed) approved the study.
RESULTS
Overall, mothers of 443 cases (nALL¼264, nAML¼172) and 324
controls participated in this study. In phase 1, 240 eligible case
(69%) and 255 eligible control (59%) mothers completed inter-
views (Spector et al, 2005). One control was excluded from analysis
because the child was found to have Down syndrome during the
interview. In phase 2, 345 potential cases were identified through
COG institutions, 240 were enroled, and 203 mothers completed
interviews (59%) (Johnson et al, 2010). We identified 267 potential
birth certificate controls, of which 70 completed and 1 partially
completed the interviews (27%) (Puumala et al, 2009). Controls
from each phase were similar enough on important demographic
factors to merge them in the current analysis (Puumala et al, 2009).
Cases and controls were similar in infant gender, birth weight,
and length of gestation, and in maternal age at index child’s birth,
previous foetal loss, and smoking during pregnancy (Table 1).
More case mothers had ohigh school diploma (34 vs 28% of
control mothers), were non-white (24 vs 15%), had a lower income
(36 vs 30% earning p$30000), experienced morning sickness
(71 vs 63%), and reported no alcohol consumption during the
index pregnancy (86 vs 79%).
Notably, 91% of case and 94% of control mothers reported
vitamin use in the year before and/or during the index pregnancy.
After adjustment for race/ethnicity and income, there were no
associations between vitamin use in the year before and/or during
pregnancy (OR¼0.79, 95% CI: 0.44–1.42), in the periconceptional
period (OR¼0.89, 95% CI: 0.64–1.24), after knowledge of
pregnancy (OR¼0.78, 95% CI: 0.48–1.28), or use over all periods
(OR¼0.84, 95% CI: 0.62–1.14) and infant leukaemia (Table 2).
Restricting exposure to use only after knowledge of pregnancy
generated comparable results with those described above (data not
shown). Similar results were observed among ALL and AML cases
analysed separately (Table 2); ORs for ALL were consistently
o1.00, whereas ORs for AML fluctuated around the null.
Stratification on MLL translocation status did not provide notable
findings (data not shown), with the exception of ALL MLLþ cases,
in whom reduced risk was suggested for exposure throughout the
periconceptional/prenatal periods (OR¼0.66, 95% CI: 0.44–1.00).




N (%) N (%) OR 95% CI
Infant characteristics
Gender
Male 156 (48.2) 218 (49.2) 1.00
Female 168 (51.9) 225 (50.8) 0.96 0.72–1.28
Birth weight
o2500g 17 (5.3) 23 (5.2) 0.99 0.52–1.90
2500–4000g 258 (79.6) 351 (79.2) 1.00
44000g 49 (15.1) 69 (15.6) 1.04 0.69–1.54
Length of gestation
o38 weeks 35 (10.8) 55 (12.4) 1.17 0.75–1.84
38–42 weeks 288 (88.9) 387 (87.4) 1.00
442 weeks 1 (0.3) 1 (0.2) 0.74 0.05–11.95
Maternal characteristics
Age at index child’s birth
o35 years 265 (82.0) 372 (84.2) 1.00
X35 years 58 (18.0) 70 (15.8) 0.86 0.59–1.26
Previous foetal loss
None 241 (74.4) 337 (76.1) 1.00
1 64 (19.8) 76 (17.2) 0.85 0.59–1.23
X2 19 (5.9) 30 (6.8) 1.13 0.62–2.05
Educational attainment
oHigh school graduate 91 (28.2) 149 (33.7) 1.47 1.02–2.11
Some post-high school 112 (34.7) 125 (28.3) 1.00
College graduate 120 (37.2) 168 (38.0) 1.25 0.89–1.77
Race/Ethnicity
White 273 (84.5) 334 (75.6) 1.00
African-American 18 (5.6) 18 (4.1) 0.82 0.42–1.60
Hispanic 15 (4.6) 55 (12.4) 3.00 1.66–5.42
Other 17 (5.3) 35 (7.9) 1.68 0.92–3.07
Household income
p$30000 95 (29.6) 157 (35.8) 1.27 0.91–1.77
$30001–75000 145 (45.2) 189 (43.1) 1.00
4$75000 81 (25.2) 93 (21.2) 0.88 0.61–1.27
Morning sickness
No 120 (37.0) 128 (28.9) 1.00
Yes 204 (63.0) 315 (71.1) 1.45 1.07–1.96
Smoking during pregnancy
No 258 (79.9) 368 (83.3) 1.00
Yes 65 (20.1) 74 (16.7) 0.80 0.55–1.15
Drinking during pregnancy
No 254 (78.6) 377 (85.7) 1.00
Yes 69 (21.4) 63 (14.3) 0.62 0.42–0.90
Abbreviations: 95% CI¼95% confidence interval; OR¼odds ratio.
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yA number of stratifications were performed to assess the
robustness of results. Across the two phases, equal proportions of
case mothers reported vitamin use (91% reported any use in both
phases) and there was no evidence of heterogeneity of the ORs
(data not shown). There was also no detectable heterogeneity on
stratification by folic acid fortification period (before, during, and
after fortification) or region of residence (six US regions and
Canada), although there was limited power to detect differences,
given smaller cell counts (data not shown).
There was no evidence of an effect of iron supplementation
anytime in the year before and/or during pregnancy (OR¼1.07,
95% CI: 0.75–1.52), in the periconceptional period (OR¼1.23,
95% CI: 0.63–2.38), after knowledge of pregnancy (OR¼1.06, 95%
CI: 0.74–1.53), or use in all periods (OR¼2.54, 95% CI: 0.69–9.39)
after accounting for race/ethnicity and income (Table 2). Among
those who reported iron supplementation, there was no association
between prescription use and infant leukaemia (data not shown).
Further analysis by leukaemic subtype (ALL vs AML, MLLþ vs
MLL ) did not yield significant findings (Table 2).
DISCUSSION
We found no evidence supporting associations between pericon-
ceptional/prenatal vitamin or iron supplementation and infant
leukaemia, either overall or for specific aetiological time periods.
These results are consistent with other reports regarding infant
leukaemia (Wen et al, 2002; Pombo-de-Oliveira and Koifman,
2006). In contrast, most childhood ALL studies have suggested
inverse associations with prenatal vitamin supplementation (with
or without iron) and/or with specific periconceptional/prenatal
periods (Sarasua and Savitz, 1994; Thompson et al, 2001; Wen
et al, 2002; Ross et al, 2005; Dockerty et al, 2007; Schuz et al, 2007;
Milne et al, 2010). However, no associations have been reported for
childhood AML (Robison et al, 1989; Ross et al, 2005; Schuz et al,
2007).
The reduced odds observed in ALL MLLþ cases may warrant
additional study, as folate deficiency is correlated with increased
DNA double-strand breaks in blood and bone marrow (Blount et al,
1997), and double-strand breaks precede MLL translocations
(Reichel et al, 1998). Further, ALL MLLþ case mothers were
expected to recall exposures similar to mothers in other subgroups.
Prenatal iron supplementation may indicate low iron levels or
anaemia, and maternal anaemia has been associated with child-
hood leukaemia (Petridou et al, 1997; Roman et al, 1997, 2005).
These observations, along with inverse associations between
prenatal iron supplementation and childhood leukaemia reported
by some (Wen et al, 2002; Kwan et al, 2007), suggest that iron
deficiency may be related to childhood leukaemia. Conversely,
there were no associations between prenatal iron supplementation
or gestational anaemia, as documented in medical records, and
infant leukaemia in phase 1 of this study (Peters et al, 2006), which
aligns with our results.
This study has strengths and limitations. It comprises the
largest study of infant leukaemia conducted to date; previous
investigations included 136 and 202 cases (Alexander et al, 2001;
Pombo-de-Oliveira and Koifman, 2006). Further, use of the COG
registry in case ascertainment results in a nearly population-based
study population, as COG institutions see B100% of leukaemia
cases aged 0–4 years (Ross et al, 1996).
Differential recall is a concern, as case mothers may exert extra
effort to accurately recall exposures. Results of validation studies
(Mackenzie and Lippman, 1989; Drews et al, 1990; Burton et al,
2001) suggest that, although accuracy of maternal supplementation
recall may vary slightly by case–control status and time period of
assessment, resulting effect estimates and aetiological inferences
are comparable. In this study, the early age of leukaemia onset
limited the recall period.
Table 2 Association of vitamin use and infant leukaemia
Controls
Combined cases ALL AML
NN OR
a 95% CI N OR
a 95% CI N OR
a 95% CI
Prenatal vitamins
Any prenatal vitamin consumption
No 19 40 1.00 28 1.00 11 1.00
Yes 303 402 0.79 0.44–1.42 235 0.63 0.34–1.18 161 1.20 0.53–2.75
Periconceptional consumption
No 100 162 1.00 104 1.00 56 1.00
Yes 222 280 0.89 0.64–1.24 159 0.77 0.54–1.11 116 1.05 0.68–1.61
Consumption during pregnancy, after confirmation of pregnancy
No 29 58 1.00 39 1.00 18 1.00
Yes 293 384 0.78 0.48–1.28 224 0.66 0.39–1.11 154 1.05 0.55–2.04
Consumption in year before and throughout pregnancy
No 137 222 1.00 137 1.00 83 1.00
Yes 185 220 0.84 0.62–1.14 126 0.77 0.55–1.09 89 0.88 0.60–1.31
Prenatal iron supplements
Any prenatal iron consumption
No 253 334 1.00 195 1.00 136 1.00
Yes 70 108 1.07 0.75–1.52 68 1.22 0.82–1.80 36 0.82 0.51–1.33
Periconceptional consumption
No 308 414 1.00 247 1.00 160 1.00
Yes 15 28 1.23 0.63–2.38 16 1.30 0.62–2.72 12 1.26 0.55–2.88
Consumption during pregnancy, after confirmation of pregnancy
No 260 345 1.00 201 1.00 141 1.00
Yes 63 97 1.06 0.74–1.53 62 1.22 0.81–1.84 31 0.77 0.46–1.27
Consumption in year before and throughout pregnancy
No 320 431 1.00 256 1.00 168 1.00
Yes 3 11 2.54 0.69–9.39 7 3.04 0.77–12.03 4 1.72 0.33–9.06
Abbreviations: 95% CI¼95% confidence interval; ALL¼acute lymphoblastic leukaemia; AML¼acute myeloid leukaemia; OR¼odds ratio.
aORs adjusted for maternal race and
household income.
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yThere are other potential sources of misclassification. Most
mothers reported taking multi- or prenatal vitamins containing
many nutrients, thereby precluding identification of aetiologically
relevant component(s). We restricted our analysis and found that
98% consumed vitamins with folic acid; ORs were nearly identical
to those in Table 2 (data not shown). We were unable to assess
total dietary folate or iron intake because of the limited food
frequency questionnaire employed in the interview. However,
dietary data from a representative sample of non-pregnant US
adults surveyed after fortification suggest that supplement use may
be a useful measure of variation in folic acid exposure (Yeung et al,
2008).
Further, we might only expect to observe an association in the
presence of folate deficiency (Robien and Ulrich, 2003); however,
US and Canadian fortification programmes increased folic acid
intake among women of childbearing age early in the study period
(Centers for Disease Control and Prevention, 2000; Honein et al,
2001; Ray et al, 2002a,b). Of note, neuroblastoma and Wilms
tumour incidence rates decreased after Canadian fortification, but
no association was observed with infant ALL (French et al, 2003;
Grupp et al, 2010). The high level of supplementation in our study
also limited statistical power.
Differential response rates across cases and controls may
indicate selection bias, as study participation (Law et al, 2002)
and prenatal vitamin use (Langley-Evans and Langley-Evans, 2002;
Williams et al, 2003) may vary by SES, race, and/or educational
attainment. Our prior analysis showed that RDD and birth
certificate controls were similar to one another; however, control
participants differed from the US population and from non-
participants on relevant demographic factors (Puumala et al,
2009). In this study, we adjusted for maternal race/ethnicity and
income, but acknowledge that residual confounding may remain.
In contrast to previous childhood leukaemia studies, we did not
observe a prenatal vitamin–infant leukaemia association. This
may be attributable to high folic acid supplementation rates,
including personal vitamin use and national fortification programs
implemented during the study period. Similarly, we did not
observe an association with iron supplmentation above that found
in multi- or prenatal vitamins.
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